CS Cancer Solutions - Structured Oncology Intelligence
Research Standards

Research Methodology

How We Source, Review, and Update Oncology Information

Evidence-based, transparent, and globally accessible.

Our Mission

CS Cancer Solutions is built on a rigorous research methodology designed to ensure that every user — patient, caregiver, clinician, or researcher — receives accurate, trustworthy, and up-to-date oncology information.

We do not provide medical advice or treatment recommendations. Instead, we offer clear, evidence-informed summaries derived from reputable scientific and clinical sources.

Evidence Hierarchy: How We Prioritize Scientific Sources

We rely on an evidence hierarchy commonly used in academic and clinical settings:

Tier 1: Authoritative National & International Sources
National Cancer Institute (NCI)
American Cancer Society (ACS)
World Health Organization (WHO)
National Institutes of Health (NIH)
Centers for Disease Control and Prevention (CDC)
Tier 2: Peer-Reviewed Scientific Literature

We continuously review oncology research published in:

PubMed / MEDLINE
ASCO journals (Journal of Clinical Oncology, etc.)
ESMO journals
Nature Cancer
Lancet Oncology
Tier 3: Clinical Trials & Emerging Research
ClinicalTrials.gov
WHO International Clinical Trials Registry Platform
EMA & FDA announcements
Tier 4: Academic Cancer Centers & Specialist Consensus
MD Anderson
Mayo Clinic
Dana-Farber
Memorial Sloan Kettering
Stanford Cancer Institute
UCSF
Global centers of excellence

Only information that aligns across multiple credible sources is included in our patient summaries.

Review & Update Schedule

Daily Monitoring
  • New clinical trials
  • Breakthrough studies
  • Updated guidelines
  • FDA approvals
  • Safety alerts
  • Major cancer conference announcements (ASCO, ESMO, AACR)
Weekly Content Refresh
  • Key educational pages are updated weekly to ensure accuracy
Monthly Peer Review Cycle
  • Sources are cross-checked
  • Outdated material is removed or clarified
  • New evidence is integrated
  • Summaries are updated for clarity and readability
Annual Comprehensive Review
  • Every section receives a full annual review to ensure long-term consistency

Translation Accuracy & Language Integrity

Our platform is written in native-quality English and Spanish, then extended through:

AI-powered translation into 100+ languages

Accurately conveys clinical terminology

Retains context and meaning

Supports culturally diverse communities

Helps hospitals serve multilingual populations

Dual-layer approach (human + AI)

How We Write & Summarize Complex Research

Patient-Friendly Without Oversimplifying

We translate complex oncology science into clear, readable summaries while preserving:

Clinical meaning
Treatment context
Research limitations
Patient considerations

Our Structured Writing Standard:

Define medical terms in plain language
Break content into digestible sections
Avoid technical jargon
Remove emotional or fear-based wording
Emphasize clarity and neutrality
No Commercial Influence or Bias

CS Cancer Solutions is independent, meaning:

No pharmaceutical advertising
No paid content
No sponsored articles
No conflicts of interest

Our mission is clarity, not commercialization.

Transparency in Limitations & Uncertainty

Science evolves — and so does our content.

We clearly state:

When evidence is emerging or inconclusive
When more research is needed
When findings conflict across studies
When recommendations vary by region or population

This builds trust with both patients and clinicians.

How We Handle Rare or Under-Studied Cancers

Rare cancers often have limited research. In these cases, we:
Focus on consensus statements
Highlight active trials
Provide specialist directory access
Identify centers of excellence
Summarize what is known and unknown
Avoid assumptions or extrapolated claims
Disclaimer & Clinical Safety

We provide education — not diagnosis.

CS Cancer Solutions does not:

Give medical advice
Replace clinician judgment
Provide personalized treatment plans
Interpret patient-specific results

We encourage all users to discuss their questions with their oncology team.

Commitment to Integrity

Our goal is to make cancer information:

Clear
Accurate
Accessible
Up-to-date
Culturally and globally relevant

Every page reflects this commitment.

Questions About Our Methodology?

Our research team is available to discuss data standards, accuracy, and partnership opportunities

Huippu Prodigy Platforms

© 2025 Huippu Prodigy Platforms, Inc.

CS Cancer Solutions, Inc. (Operating Company)

Evidence-Governed • Informed by Current Peer-Reviewed Research

Independent, Unbiased Oncology Intelligence